Gilead Sciences Inc. (GILD): A Defensive Stock with Growing Popularity
Gilead Sciences, Inc. (NASDAQ:GILD) has been gaining popularity as a defensive stock, and for good reason. The company has transitioned away from its volatile COVID-19 treatment revenue from Veklury and is now focused on its core business in HIV and a growing oncology pipeline. This provides the firm with high-visibility, non-discretionary earnings, making it an attractive option for investors looking for a stable and predictable return.
The defensive strength of Gilead Sciences lies in its dominant position in the HIV market, which functions similarly to a utility because the treatments are life-sustaining and non-discretionary. HIV treatment is a highly predictable business, with patients rarely switching treatments once stabilized, creating a highly predictable cash flow that is unaffected by broader economic cycles.
Gilead’s HIV Portfolio
Gilead’s HIV portfolio generated $20.8 billion in 2025, and the company is expected to continue to dominate the market in the coming years. During the Barclays Healthcare Conference in March, CFO Andrew Dickinson emphasized that Gilead faces no major loss of exclusivity until 2036, providing a level of safety that is rare in the pharma sector.
One of the key drivers of Gilead’s growth is its oncology pipeline, which now accounts for about 12% of total revenue. Products like Trodelvy and cell therapies are seeing double-digit growth, providing a growth kicker on top of the defensive HIV base. This diversification of the company’s risk across different therapeutic areas makes it a more attractive option for investors.
Dividend Yield and Growth
Gilead Sciences, Inc. (NASDAQ:GILD) stock is a favorite among income-focused funds due to its aggressive cash return to shareholders. In February, the board raised the quarterly dividend to $0.82 per share, marking another year of consecutive growth. As of April, the forward dividend yield stands at approximately 2.4%, backed by a healthy non-GAAP EPS guidance of $8.45–$8.85 for the full year.
For investors looking for a defensive stock with a strong track record of dividend growth, Gilead Sciences is certainly worth considering. The company’s commitment to returning cash to shareholders, combined with its dominant position in the HIV market and growing oncology pipeline, make it an attractive option for investors looking for a stable and predictable return.
Comparison to Other Defensive Stocks
While Gilead Sciences is a strong defensive stock, it’s not the only option available to investors. Other best defensive stocks include companies like Johnson & Johnson, Procter & Gamble, and Coca-Cola. These companies have a long history of stability and predictability, making them attractive options for investors looking for a defensive stock.
Conclusion
In conclusion, Gilead Sciences, Inc. (NASDAQ:GILD) is a defensive stock with growing popularity due to its dominant position in the HIV market, growing oncology pipeline, and commitment to returning cash to shareholders. The company’s strong track record of dividend growth, combined with its predictable cash flow and level of safety, make it an attractive option for investors looking for a stable and predictable return.